Here is the list of the research litterature that was reviewed. We have been able to secure a number of the studies for your review.  If there is one that you are particulary interested in and the link is not provided, please contact us at info@mapleleafmedical.com and we will do our best to assist you.

1. Carr, A., et al., A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids, 1998. 12(7): p. F51-8.
   
   
2. Kingsley, L., Pewen, WF, Calhoun, BC, Riddler, SA, Rinaldo, CR, Mellors, J, Palella, F, Cumulative nucleoside exposure as a prognostic marker for development of HIV-associated lipodystrophy syndrome., in 15th International AIDS Conference. 2004: Bangkok, Thailand.
   
   
3. Lichtenstein, K.A., Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr, 2005. 39(4): p. 395-400.
   
   
4. Gripshover, B., Tien, PC, Saag, M, Osmond, D, Bacchetti, P, Grunfeld, C; Investigators of the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study, Lipoatrophy is the Dominant Feature of the Lipodystrophy Syndrome in HIV-infected Men, in 10th Conference on Retroviruses and Opportunistic Infections. 2003.
   
   
5. Heath, K.V., et al., Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. Aids, 2001. 15(2): p. 231-9.
   
   
6. Mynarcik, D.C., et al., Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr, 2000. 25(4): p. 312-21.
   
   
7. Jacobson, D.L., et al., Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis, 2005. 40(12): p. 1837-45.
   
   
8. Carr, A., et al., An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet, 2003. 361(9359): p. 726-35.
   
   
9. Rubio, R., Torralba, M, Antela, A, Dronda, F, Costa, R, Moreno, S, Body shape abnormalities in a cohort of HIV-infected patients on first-line HAART, in 8th Conference on Retroviruses and Opportunistic Infections. 2001.
   
   
10. Pujari, S.N., et al., Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr, 2005. 39(2): p. 199-202.
    
    
11. Milinkovic, A. and E. Martinez, Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother, 2005. 56(1): p. 6-9.
    
    
12. Yang, Y., et al., Facial fat volume in HIV-infected patients with lipoatrophy. Antivir Ther, 2005. 10(4): p. 575-81.
    
    
13. Carr, A., et al., Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Jama, 2002. 288(2): p. 207-15.
    
    
14. Galli, M., et al., Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med, 2002. 162(22): p. 2621-8.
    
    
15. Lichtenstein, K.A., et al., Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr, 2003. 32(1): p. 48-56.
    
    
16. Martinez, E., et al., Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet, 2001. 357(9256): p. 592-8.
    
    
17. Mascolini, M., A Look at Lipoatrophy Predictors and Reversers, in 10th European AIDS Conference. 2005, NATAP: Dublin, Ireland.
    
    
18. Barata, A., Domingo, P, Sambeat, MA, Fuster, M, Cadafalch, J, Ros, S, Wulff, J., Psycho-social impact of facial lipoatrophy in HIV+ patients on antiretroviral treatment., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
19. Marin, A., Casado, JL, Moya, J, Aranzabal, L, Antela, A, Moreno, A, Dronda, F, Moreno, S., Quality of life and related psychological factors in HIV-infected patients with Lipodystrophy Syndrome., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
20. Capeau, J., Progress in Understanding the Pathogenesis of HIV-1 Related Lipodystrophy., in Conf Retroviruses Opportunistic Infect. 2003.
    
    
21. Martin, A. and P.W. Mallon, Therapeutic approaches to combating lipoatrophy: do they work? J Antimicrob Chemother, 2005. 55(5): p. 612-5.
    
    
22. Bastard, J.P., et al., Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet, 2002. 359(9311): p. 1026-31.
    
    
23. Maher, B., et al., Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters. Antivir Ther, 2004. 9(6): p. 879-87.
    
    
24. Maher, B., et al., TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. Aids, 2002. 16(15): p. 2013-8.
    
    
25. Cherry, C.L., et al., Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr, 2005. 38(3): p. 263-7.
    
    
26. McComsey, G.A., et al., Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. Aids, 2005. 19(1): p. 15-23.
    
    
27. Buffet, M., et al., Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol, 2005. 33(1): p. 60-4.
    
    
28. Walker, U.A., et al., Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr, 2002. 29(2): p. 117-21.
    
    
29. Shikuma, C.M., et al., Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. Aids, 2001. 15(14): p. 1801-9.
    
    
30. Shiramizu, B., Westgard, E, Cossarizza, A, Pinti, M, Shikuma, C, Competitive PCR-analysis of subcutaneous adipose tissue mitochondrial DNA from individuals with highly active antiretroviral therapy-associated lipodystrophy., in 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2001: Athens, Greece.
    
    
31. Van der Valk, M., et al., Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther, 2004. 9(3): p. 385-93.
    
    
32. Kakuda, T.N., Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther, 2000. 22(6): p. 685-708.
    
    
33. Walker, U.A., et al., Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther, 2003. 8(5): p. 463-70.
    
    
34. Sutinen, J., Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis, 2005. 18(1): p. 25-33.
    
    
35. Engelhard, P., Knies, M., Safety and efficacy of New-Fill (Polylactic acid) in the treatment of HIV-Associated Lipoatrophy of the face (HALF). in 14th Int Conf AIDS. 2002: Barcelona, Spain.
    
    
36. Lafaurie, M., Dolivo, J, Boulu, D, Madelain, I, Molina, JM., Treatment of HIV-Associated Lipoatrophy of the Face with Intradermal Injections of Polylactic Acid., in Conf Retroviruses Opportunistic Infect. 2002.
    
    
37. Moyle, G., Lysakova, L, Brown, S, Barton, S., Polylactate (New-Fill) Injections Subjectively and Objectively Improve Appearance and Reduce Anxiety and Depression Scores in HIV Positive Persons with Facial Lipoatrophy: A Randomised, Open Label, Immediate vs. Delayed Therapy Study., in Intersci Conf Antimicrob Agents Chemother 2002.
    
    
38. Valantin, M., Aubron-Olivier, C, Ghosn, J. Laglenne, E, Pauchard, M, Schoen, H, Katz, P, Costagliola, D, Katlama, C; Vega Study Group., Polylactic Acid Implants (New-Fill) in the Correction of Facial Lipoatrophy in HIV-infected Patients (VEGA Study): Results at 72 weeks., in Conf Retroviruses Opportunistic Infect. 2003.
    
    
39. Carey, D., et al., Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. Aids, 2005. 19(12): p. 1325-1327.
    
    
40. Benn, P., et al., Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? HIV Med, 2003. 4(4): p. 325-31.
    
    
41. Yang, Y. and N.I. Paton, Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility. HIV Med, 2005. 6(5): p. 321-5.
    
    
42. Dion, E., Valantin, MA, Biligui, A, Grenier, P, Katlama, C, Costagliola, D., 3D Computed Tomography to Evaluate Lipoatrophy in HIV Infected Patients., in IAS Conference on HIV Pathogenesis and Treatment - 2nd: 2003: Paris, France. 2003: Paris, France.
    
    
43. Viciana, P., Lopez-Cortes, LF, Alarcon, A, Cordero, E, Garcia-Luna, PP, Pachon, J., Facial lipoatrophy associated with HAART: usefulness of cheek measure and factors associated., in Conf Retroviruses Opportunistic Infect. 2001.
    
    
44. McComsey, G.A., et al., Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis, 2004. 38(2): p. 263-70.
    
    
45. Evans, A., Bor, R, Johnson, MA, The psychological impact of HIV related lipodystrophy., in 14th Int Conf AIDS. 2002.
    
    
46. Forrester, J., Whittaker, W, Workman, C., Peripheral fat depletion (lipoatrophy) & other body shape changes - impact on psychosocial quality of life., in 13th Int Conf AIDS. 2000.
    
    
47. Marin, A., Casado, JL, Aranzabal, L, Moya, J, Antela, A, Moreno, A, Dronda, F, Moreno, S., Identification of factors related to social distress and anxiety in HIV-infected patients with Lipodystrophy Syndrome., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
48. Marin, A., Casado, JL, Moya, J, Aranzabal, L, Antela, A, Moreno, A, Perez-Elias, MJ, Moreno, S., Depression as consequence of the lipodystrophy syndrome in HIV-infected patients., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
49. Fumaz, C., Munoz-Moreno, JA, Ferrer, MJ, Negredo, E, Martinez, JC, Martinez, E, Adell, X, Higueras, C, Gonzalez Mestre, VP, Clotet, B., Psychological assessment of HIV-infected patients with facial lipoatrophy before and after reparatory treatment., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
50. Price, B., Cummings, R, Mijch, A, Archer, B, Bowtell-Harris, C, Hoy, J., New-Fill: Facing the challenges of lipoatrophy., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
51. Blanch, J., et al., Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr, 2002. 31(4): p. 404-7.
    
    
52. Burgoyne, R., et al., The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res, 2005. 14(4): p. 981-90.
    
    
53. Nicholas, P.K., et al., Lipodystrophy and quality of life in HIV: symptom management issues. Appl Nurs Res, 2005. 18(1): p. 55-8.
    
    
54. Ammassari, A., et al., Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr, 2002. 31 Suppl 3: p. S140-4.
    
    
55. Corless, I.B., et al., Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS, 2005. 19(9): p. 577-86.
    
    
56. 56.   Duran, S., et al., Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. Aids, 2001. 15(18): p. 2441-4.
    
    
57. 57.   Santos, C.P., et al., Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. Aids, 2005. 19 Suppl 4: p. S14-21.
    
    
58. Carrieri, P., Cailleton, V, Le Moing, V, Spire, B, Dellamonica, P, Bouvet, E, Raffi, F, Journot, V, Moatti, J, APROCO study group, The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort. JAIDS Journal of Acquired Immune Deficiency Syndromes, 1 November 2001. Volume 28(3): p. 232-239.
    
    
59. Kasper, T., Arboleda, CH, Halpern, M, The impact of patient perceptions of body shape changes and metabolic abnormalities on antiretroviral therapy., in 13th Int Conf AIDS. 2000.
    
    
60. Martin, A., et al., Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Aids, 2004. 18(7): p. 1029-36.
    
    
61. Hanvanich, M., Prasanthai, V, Riengchan, P, Arunyingmongkol, K, Intalapaporn, P, Hiransuthikul, N, Suankratay, C, Kulwichit, W., Reduction of d4T dosage improves lipoatrophy without virologic failure., in IAS Conference on HIV Pathogenesis and Treatment - 2nd: 2003: Paris, France. 2003, Antivir Ther: Paris, France.
    
    
62. Milinkovic, A., Lopez, S, Vidal, S, Miro, O, Fernandez, X, Arnaiz, J, Blanco, J, Leon, A, Larrousse, M, Lonca, M, Laguno, M, Mallolas, J, Gatell, J, Martinez, E, A Randomized Open Study Comparing the Effect of Reducing Stavudine Dose vs Switching to Tenofovir on Mitochondrial Function, Metabolic Parameters, and Subcutaneous Fat in HIV-infected Patients Receiving Antiretroviral Therapy Containing Stavudine, in 12th Conference on Retroviruses and Opportunistic Infections. 2005: Boston, MA.
    
    
63. Gallant, J.E., et al., Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama, 2004. 292(2): p. 191-201.
    
    
64. Moyle, G., Sabin, C, Cartledge, J, Johnson, M, Wilkins, E, Churchill, D, Hay, P, Fakoya A, Murphy, M, Scullard, G, Leen, C, Reilly, G, The Rave Study Group, A 48-week, Randomized, Open-label Comparative Study of Tenofovir DF vs Abacavir as Substitutes for a Thymidine Analog in Persons with Lipoatrophy and Sustained Virological Suppression on HAART, in 12th Conference on Retroviruses and Opportunistic Infections. 2005: Boston, MA.
    
    
65. Carr, A., et al., HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. Aids, 2001. 15(14): p. 1811-22.
    
    
66. Martin, A., et al., Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). HIV Clin Trials, 2004. 5(4): p. 192-200.
    
    
67. Antoniou, T., et al., Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med, 2005. 6(4): p. 284-90.
    
    
68. Mauss, S., F. Berger, and G. Schmutz, Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. Aids, 2005. 19(1): p. 93-5.
    
    
69. Rifkin, B.S. and M.A. Perazella, Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med, 2004. 117(4): p. 282-4.
    
    
70. Gey, D., Lorenz, T, Brust, J, Klinker, H, Langmann, P, Mosthaf, F, Schuster, D, Hartmann, M., An NRTI-free regimen in HIV-patients with evidence of mitochondrial toxicity: 48 week results of a pilot study., in 15th International AIDS Conference. 2004: Bangkok, Thailand.
    
    
71. Carr, A., et al., No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet, 2004. 363(9407): p. 429-38.
    
    
72. Hadigan, C., et al., Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med, 2004. 140(10): p. 786-94.
    
    
73. Sutinen, J., et al., Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antivir Ther, 2003. 8(3): p. 199-207.
    
    
74. Honda, M., Nakayama, T, Setoguchi, T, Takahashi, N, Tanuma, J, Suzuki, Y, Kikuchi, Y, Tachikawa, N, Teruya, K, Gatanaga, H, Genka, I, Kimura, S, Oka, S., Prospective study of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
    
    
75. Koutkia, P., et al., Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. Jama, 2004. 292(2): p. 210-8.
    
    
76. Levin, J. Experimental Uridine Therapy for Lipoatrophy. in 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2004. Washington, D.C.
    
    
77. Walker, U.A., Update on mitochondrial toxicity: where are we now? J HIV Ther, 2003. 8(2): p. 32-5.
    
    
78. Walker, U.A., et al., Beneficial effects of oral uridine in mitochondrial toxicity. Aids, 2004. 18(7): p. 1085-6.
    
    
79. Bickel, M., Zangos, S, Jacobi, V, Lutz, T, Goebel, F, Staszewski, S, Klauke, S, Effects of Recombinant Human Growth Hormone (r-hGH) on Fat Depletion and Plasma Lipids in HIV-1 Infected Patients With Lipodystrophy - A Randomised, Open-label Study, in 12th Conference on Retroviruses and Opportunistic Infections. 2005: Boston, MA.
    
    
80. Engelson, E.S., et al., Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr, 2002. 30(4): p. 379-91.
    
    
81. Lo, J.C., et al., The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab, 2001. 86(8): p. 3480-7.
    
    
82. McComsey, G.A., Setzer, B., O'Riordan, M., et al., NucleomaxX improves clinical lipoatrophy without any change in fat mitochondrial DNA levels., in 10th European AIDS Conference. 2005: Dublin, Ireland.
    
    
83. Sutinen, J., Walker, U.A., Hakkinen, A.M., et al., Uridine for the treatment of HAART-associated lipodystrophy: a randomized, double-blind, placebo-controlled trial., in 10th European AIDS Conference. 2005: Dublin, Ireland.
    
    
84. Moyle, G. Lipodystrophy Meeting Report: lipoatrophy; facial fillers. in 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2004. Washington, D.C.
    
    
85. Burgess, C.M. and R.M. Quiroga, Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol, 2005. 52(2): p. 233-9.
    
    
86. Vochelle, D., The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience. Semin Cutan Med Surg, 2004. 23(4): p. 223-6.
    
    
87. Lafaurie, M., Dolivo, M, Boulu, D, Finel, H, Porcher, R, Madelaine, I, Furco, A, Pavie, J, Decastro, N, Molina, JM., Treatment of Facial Lipoatrophy with Injections of Polylactic Acid in HIV-infected Patients: Results from a Cohort of 94 Patients., in 11th Conf Retrovir Opportunistic Infect. 2004: San Francisco, CA.
    
    
88. Lafaurie, M., et al., Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr, 2005. 38(4): p. 393-8.
    
    
89. Valantin, M.A., et al., Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. Aids, 2003. 17(17): p. 2471-7.
    
90. Sterling, J.B. and C.W. Hanke, Poly-L-lactic acid as a facial filler. Skin Therapy Lett, 2005. 10(5): p. 9-11.
    
    
91. Moyle, G.J., et al., A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med, 2004. 5(2): p. 82-7.
    
    
92. Borelli, C., et al., Deep Subcutaneous Application of Poly-L-Lactic Acid as a Filler for Facial Lipoatrophy in HIV-Infected Patients. Skin Pharmacol Physiol, 2005. 18(6): p. 273-278.
    
    
93. Pacini, S., et al., Bio-Alcamid, a novel prosthetic polymer, does not interfere with morphological and functional characteristics of human skin fibroblasts. Plast Reconstr Surg, 2003. 111(1): p. 489-91.
    
    
94. Ramires, P.A., et al., In vitro and in vivo biocompatibility evaluation of a polyalkylimide hydrogel for soft tissue augmentation. J Biomed Mater Res B Appl Biomater, 2005. 72(2): p. 230-8.
    
    
95. Pacini, S., et al., Bio-alcamid: a novelty for reconstructive and cosmetic surgery. Ital J Anat Embryol, 2002. 107(3): p. 209-14.
    
    
96. Formigli, L., et al., Bio-Alcamid: an electron microscopic study after skin implantation. Plast Reconstr Surg, 2004. 113(3): p. 1104-6.
    
    
97. Claoue, B.L. and P. Rabineau, The polyalkylimide gel: experience with Bio-Alcamid. Semin Cutan Med Surg, 2004. 23(4): p. 236-40.
    
    
98. Love, A.a.L.C.C., Facial lipoatrophy as part of Lipodystrophy Syndrome secondary to HIV, in SurgiNews. 2004. p. 7-9.
    
    
99. Protopapa, C., et al., Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther, 2003. 5(3-4): p. 226-30.
    
100. Loutfy, M.R., Kovacs, C.M., Raboud, J., Halpenny, R., Beninger, F. . Pilot Study of the Safety, Clinical Efficacy and Impact on Quality of Life of Using Bio-AlcamidTM for the Reconstructive Treatment of Antiretroviral-Induced Facial Lipoatrophy in HIV-Positive Individuals. in CAHR. 2005.
     
     
101. Guaraldi, G., et al., Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis, 2005. 40(2): p. e13-5.
     
     
102. Burnouf, M., et al., Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique. Arch Dermatol, 2005. 141(10): p. 1220-4.
     
     
103. Coleman, S.R., Long-term survival of fat transplants: controlled demonstrations. Aesthetic Plast Surg, 1995. 19(5): p. 421-5.
     
     
104. Negredo, E., Martinez, JC, Fumaz, CR, Martinez, E, Higueras, C, Adell, X, Munoz-Moreno, JA, Gonzalez-Mestre, V, Clotet, B., Open pilot clinical trial to evaluate the efficacy of reparatory treatment in facial lipoatrophy secondary to antiretroviral treatment., in 15th Int Conf AIDS. 2004: Bangkok, Thailand.
     
     
105. Guaraldi, G., Orlando, G., Vandelli, M., DePaola, M., Comelli, D, De Santis, G., Pedone, A., Spaggiari, A., Baccarani, A., Pinelli, M., De Fazio, D., Blini, M., Borghi, V., Nardini, G., Beghetto, B., and Esposito, R., Psychometric evaluation in patients undergoing fillers injections for the treatment of HIV-related facial lipoatrophy: polylactic acid versus polyacrylamide, in 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 2005: Dublin, Ireland.
     
     
106. Gooderham, M. and N. Solish, Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg, 2005. 31(1): p. 104-8.
     
     
107. James, J., A. Carruthers, and J. Carruthers, HIV-associated facial lipoatrophy. Dermatol Surg, 2002. 28(11): p. 979-86108.          
     
     
108. Jones, D.H., et al., Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg, 2004. 30(10): p. 1279-86.